Earnings Call Summary | Gilead Sciences(GILD.US) Q1 2024 Earnings Conference
Earnings Call Summary | Gilead Sciences(GILD.US) Q1 2024 Earnings Conference
The following is a summary of the Gilead Sciences, Inc. (GILD) Q1 2024 Earnings Call Transcript:
以下是吉利德科學公司（GILD）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Gilead's Q1 total product sales, excluding Veklury, grew 6% year-over-year to $6.1 billion, bolstered by an increased demand across HIV, oncology, and liver disease sectors.
Veklury sales for COVID-19 treatments reached a total of 555 million.
1Q non-GAP diluted EPS stood at $1.82, surpassing expectations due to higher product sales.
However, their Q1 2024 haven't met expectations with diluted earnings per share at a negative $1.32, compared to a positive $1.37 for the same period the previous year.
Product gross margin fell to 85.4% due primarily to product mix, and operating expenses decreased by 2%.
吉利德第一季度的產品總銷售額（不包括Veklury）同比增長6％，達到61億美元，這得益於艾滋病毒、腫瘤和肝病領域需求的增加。
Veklury COVID-19 治療的總銷售額達到了 5.55 億次。
由於產品銷售增加，第一季度非GAP攤薄後每股收益爲1.82美元，超出預期。
但是，他們的2024年第一季度並未達到預期，攤薄後的每股收益爲負1.32美元，而去年同期爲正1.37美元。
產品毛利率降至85.4％，這主要是由於產品組合，運營費用下降了2％。
Business Progress:
業務進展：
HIV product sales saw a 4% increase year-over-year, and oncology product sales were up by 18%, propelled by Trodelvy.
Gilead completed the acquisition of CymaBay, resulting in a seladelpar drug with the potential to treat significant unmet need in liver disease.
Phase 1b data on the twice-yearly parenteral program of Lenacapavir plus two broadly neutralizing antibodies, potentially the first twice-yearly subcutaneous HIV prevention option, was shared.
Gilead showed enthusiasm for the release of their drug, Trodelvy, for treating diverse segments of the breast cancer population.
Gilead will be particularly focusing on expense management, aiming to drive substantial growth in their business over the next decade while providing good returns to investors.
在Trodelvy的推動下，HIV產品的銷售同比增長了4％，腫瘤產品的銷售增長了18％。
吉利德完成了對CymaBay的收購，從而開發出了一種seladelpar藥物，有可能治療大量未滿足的肝病需求。
分享了每年兩次的來那卡韋注射計劃以及兩種廣泛中和的抗體（可能是第一個每年兩次的皮下HIV預防方案）的1b期數據。
吉利德對他們的藥物Trodelvy的發佈表現出熱情，該藥物用於治療乳腺癌人群的不同群體。
吉利德將特別關注費用管理，旨在推動其業務在未來十年實現大幅增長，同時爲投資者提供豐厚的回報。
More details: Gilead Sciences IR
更多詳情： 吉利德科學紅外線
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。